JP2013531070A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531070A5
JP2013531070A5 JP2013520827A JP2013520827A JP2013531070A5 JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5 JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5
Authority
JP
Japan
Prior art keywords
oxadiazol
benzyl
ethyl
acid
azetidinecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013520827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531070A (ja
JP5788507B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044597 external-priority patent/WO2012012477A1/en
Publication of JP2013531070A publication Critical patent/JP2013531070A/ja
Publication of JP2013531070A5 publication Critical patent/JP2013531070A5/ja
Application granted granted Critical
Publication of JP5788507B2 publication Critical patent/JP5788507B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013520827A 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物 Expired - Fee Related JP5788507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36592310P 2010-07-20 2010-07-20
US61/365,923 2010-07-20
PCT/US2011/044597 WO2012012477A1 (en) 2010-07-20 2011-07-20 Substituted 3-phenyl-1,2,4-oxadiazole compounds

Publications (3)

Publication Number Publication Date
JP2013531070A JP2013531070A (ja) 2013-08-01
JP2013531070A5 true JP2013531070A5 (https=) 2015-07-23
JP5788507B2 JP5788507B2 (ja) 2015-09-30

Family

ID=44628993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520827A Expired - Fee Related JP5788507B2 (ja) 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物

Country Status (6)

Country Link
US (1) US8822510B2 (https=)
EP (1) EP2595969B1 (https=)
JP (1) JP5788507B2 (https=)
CN (1) CN103124727B (https=)
ES (1) ES2539256T3 (https=)
WO (1) WO2012012477A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2619190B1 (en) * 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases
EP2867230B1 (en) 2012-07-02 2020-02-12 Monsanto Technology LLC Process for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
US8859598B2 (en) * 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
US8957051B2 (en) 2012-10-04 2015-02-17 Allergan, Inc. Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
WO2015073140A1 (en) * 2013-11-14 2015-05-21 Allergan, Inc. 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
WO2015108577A1 (en) * 2014-01-15 2015-07-23 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
TWI689487B (zh) 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
DK3373931T3 (da) * 2015-11-13 2022-11-28 Oppilan Pharma Ltd Heterocykliske forbindelser til behandling af sygdom
WO2019101511A1 (en) * 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
CN115197282B (zh) * 2021-04-12 2024-10-11 中科催化新技术(大连)股份有限公司 一种吡喃糖苷衍生物的制备方法
CN115197186B (zh) * 2021-04-12 2024-04-16 中科催化新技术(大连)股份有限公司 一种生物质基吡喃糖苷衍生物的制备方法
CN116375671A (zh) * 2021-12-24 2023-07-04 晶美晟光电材料(南京)有限公司 一种包含四氢吡喃结构的液晶化合物的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
US7309721B2 (en) 2002-03-01 2007-12-18 Merck + Co., Inc. Aminoalkylphosphonates and related compounds as Edg receptor agonists
JP2005533058A (ja) * 2002-06-17 2005-11-04 メルク エンド カムパニー インコーポレーテッド Edg受容体アゴニストとしての1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)アゼチジン−3−カルボキシラートおよび1−((5−アリール−1,2,4−オキサジアゾール−3−イル)ベンジル)ピロリジン−3−カルボキシラート
BRPI0410439A (pt) 2003-05-19 2006-06-06 Irm Llc compostos e composições imunossupressoras
US7605171B2 (en) 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
CN1950349A (zh) 2004-05-04 2007-04-18 默克公司 作为用于治疗或预防糖尿病的二肽基肽酶-ⅳ抑制剂的1,2,4-噁二唑衍生物
AU2005299851B2 (en) 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
AU2006214314B2 (en) 2005-02-14 2012-02-09 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
BRPI0609668A2 (pt) 2005-03-23 2011-10-18 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2007024922A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2009530389A (ja) * 2006-03-21 2009-08-27 エピックス デラウェア, インコーポレイテッド S1p受容体調節化合物及びその使用
MX2008012738A (es) 2006-04-03 2009-02-06 Astellas Pharma Inc Heterocompuesto.
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-4-基衍生物
TWI408139B (zh) 2006-09-07 2013-09-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
MX2009002915A (es) 2006-09-21 2009-03-31 Actelion Pharmaceuticals Ltd Derivados de fenilo y su uso como inmunomoduladores.
SG177221A1 (en) * 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
PT2125797E (pt) 2007-03-16 2014-03-11 Actelion Pharmaceuticals Ltd Derivados aminopiridina como agonistas do receptor s1p1/edg1
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
ES2622423T3 (es) 2007-10-04 2017-07-06 Merck Serono S.A. Derivados de oxadiazol
RU2010121969A (ru) 2007-11-01 2011-12-10 Актелион Фармасьютиклз Лтд (Ch) Новые производные пиримидина
US20110275673A1 (en) * 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
JP5728487B2 (ja) 2009-10-29 2015-06-03 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 三環式ヘテロ環化合物
WO2011133734A1 (en) 2010-04-23 2011-10-27 Bristol-Myers Squibb Company 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
WO2012061459A1 (en) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases

Similar Documents

Publication Publication Date Title
JP2013531070A5 (https=)
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2012528178A5 (https=)
JP2018535999A5 (https=)
JP2005536475A5 (https=)
JP2011502958A5 (https=)
JP2016538313A5 (https=)
JP2004502670A5 (https=)
JP2019537605A5 (https=)
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2014530900A5 (https=)
JP2011509309A5 (https=)
JP2019537603A5 (https=)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2010508338A5 (https=)
JP2018502906A5 (https=)
JP2014523851A5 (https=)
JP2009525340A5 (https=)
JP2013509431A5 (https=)
JP2012515787A5 (https=)
JP2011506469A5 (https=)
JP2010516700A5 (https=)
JP2013501729A5 (https=)
RU2003112610A (ru) Производные пиразола для лечения вирксных заболеваний